ClinicalTrials.gg
CompletedNCT01431690Updated Apr 24, 2015

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

A Phase 1 interventional study of warfarin and omefas in Hypertriglyceridemia, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-24.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing omacor in Hypertriglyceridemia — none open to participants now, none under way, none of them phase 3. Omacor · Hypertriglyceridemia.

Enrollment
9th of 21
52 · median 48
Started
2011
with 3 others
Phase 1
4 of 21
none open now
Registered
17th of 21
by date
Lead sponsor
4 of 21
AstraZeneca

Among the 21 studies testing omacor in Hypertriglyceridemia, this one is the 9th largest by enrollment, is one of 4 that started in 2011, is one of 4 in phase 1, and was the 17th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

None of the 21 studies testing omacor in Hypertriglyceridemia is open now. The open studies under Hypertriglyceridemia, anywhere →

About omacor

Omacor: first FDA approval 2004 (LOVAZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing omacor in Hypertriglyceridemia as a file.
02

Study summary

The primary objective of this study is to determine the effect of Epanova® on the pharmacokinetic and anticoagulant activity of warfarin.

The secondary objective of this study is to compare the systemic exposure of EPA and DHA following multiple-dose administration of Epanova®, a free fatty acid mixture, to Lovaza®, a mixture of fatty acid ethyl esters, under low-fat meal conditions since these products are likely to be administered to patients with cardiovascular disease who are recommended to consume low-fat meals.

03

Conditions studied

  • Hypertriglyceridemia

Browse trials for

Keywords

  • Eicosapentaenoic Acid
  • Docosahexaenoic Acid
  • Warfarin
  • Hypertriglyceridemia
  • Omega-3 free fatty acids
  • Omega-3 ethyl ester acids
  • Epanova
  • Lovaza
  • pharmacokinetics
  • low-fat meal
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject candidates must fulfill all of the following inclusion criteria to be eligible for participation in the study:

  1. Healthy adult male and/or females, 18 to 55 years of age (inclusive).
  2. (BMI) ≥ 18 and ≤ 29.9 (kg/m2).
  3. Medically healthy with clinically insignificant screening results. must be ≥ the lower limit of normal.
  4. Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to dosing.
  5. Voluntarily consent to participate in the study and to follow the restrictions and procedures outlined for the study.
  6. For the Warfarin and Epanova Arm, females must be of non- defined as have undergone sterilization procedures at least 6 months prior to check-in or have been for at least 24 consecutive months prior to check-in of the study and have a screening follicle stimulating hormone level > 40 mIU/mL.
  7. For the Lovaza Arm, females may be of non-childbearing potential (as outlined above for Warfarin and Lovaza) or be of childbearing potential and must either be sexually inactive (abstinent) for 14 days prior to screening and remain so through 30 days following the final dosing of the study drug or until completion of the subject's first menstrual cycle following the final dosing of the study drug, whichever period of time is longer or have been using one of the acceptable methods of .

Exclusion criteria

Exclusion Criteria:

Subjects may be excluded from the study if there is evidence of any of the following criteria at screening, check-in, or at any time during the study as appropriate.

For both arms (Warfarin and Epanova, Lovaza)

  1. Has a history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal (GI), endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
  2. Has a positive urine drug/alcohol testing at screening or check-in.
  3. Has a positive testing for (HIV), surface antigen (HBsAg), or antibodies (HCV).
  4. Has consumed fish within 7 days prior to check-in.
  5. Has used fish oil, other EPA and/or DHA containing supplements within 2 months of check-in.
  6. Has a history or presence of alcoholism or drug abuse within the 2 years prior to check-in.
  7. Has a known sensitivity or allergy to soybeans, fish, and/or shellfish.
  8. Has had a or idiosyncratic reaction to compounds related to Epanova® and Lovaza®.
  9. Has used any prescription medication (with the exception of hormonal for females in the Lovaza arm) within 14 days prior to check-in.
  10. Has used any over-the-counter (OTC) medication, including herbal products (e.g., bromelains, danshen, dong quai [Angelica sinesis], garlic, ginko biloba, ginseng, and St. John's wort), within the 7 days prior to check-in. Up to 2 g per day of acetaminophen is allowed at the discretion of the PI for the Lovaza arm.
  11. Has used any drugs known to significantly inhibit [strong or moderate] or induce liver enzymes involved in drug metabolism [CYP P450]) within 30 days prior to check-in.
  12. Has donated blood or has had a significant blood loss within 56 days prior to check-in.
  13. Has donated plasma within 7 days prior to check-in.
  14. Has participated in another clinical trial within 30 days prior to check-in.
  15. Is a female who is pregnant or lactating.

For Warfarin and Epanova Arm only:

  1. Has taken large daily doses of Vitamin K (exceeding 25 μg/day) or has eaten large quantities (e.g., averaging > 4 portions daily) of dark green/leafy vegetables (e.g., spinach, kale, collard greens, broccoli, Brussels sprouts) during the 2 months prior to check-in.
  2. Is employed or involved in any circumstance which would place them at increased risk of hemorrhage (e.g., contact sports, strenuous or unaccustomed weight lifting, running, bicycling).
  3. Has a personal or familial history of bleeding disorder(s), thromboembolic disease, clinical GI bleeding, or any history of GI surgery except uncomplicated appendectomy or cholecystectomy, or colorectal surgery for polyps, nonmalignant tumors, or diverticula.
  4. Has active severe gingivitis.
  5. Has had a hypersensitivity or idiosyncratic reaction to compounds related to warfarin.
  6. Has a recent physical injury (within the 2 weeks prior to screening).
  7. Has had a major surgery within the 3 months prior to screening.
  8. Is allergic to Vitamin K.
  9. Has used non-steroidal anti-inflammatory (NSAID) drugs within the 2 weeks prior to check-in.
  10. Has a positive fecal occult blood sample at check-in.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Warfarin and Epanova

    Drug: warfarin · Drug: omefas

  • Active comparator
    Lovaza

    Drug: omega-3-acid ethyl esters

Interventions

  • A single 25 mg dose of warfarin

    Also known as: coumarin-based anticoagulant

  • Drugomefas

    4 x 1 g capsule dose of Epanova®

    Also known as: Epanova

  • 4 x 1 g capsule dose of Lovaza®

    Also known as: Lovaza

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of R- and S- warfarin

    The primary endpoints of this study will be the area under the curve (AUC)0-t, AUC0-inf, and maximum concentration (Cmax) of R- and S warfarin and the maximum International Normalized Ratio (INRmax) over 168 hours postdose and INR AUC0-168 when warfarin is administered with and without Epanova®.

    Time frame: 168 hours

  2. Pharmacodynamics of R- and S- warfarin

    The INRmax over 168 hours postdose and INR AUC0-168 when warfarin is administered with and without Epanova®.

    Time frame: 168 hours

Secondary outcomes

  1. Total EPA+DHA

    The AUC0-tau and Cmax of baseline-adjusted total EPA+DHA following multiple doses (14 days) of Epanova® and Lovaza®.

    Time frame: 24 hours

07

Study locations

1 site
  • Tempe, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2011
First posted
Sep 9, 2011
Start
Aug 2011
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Last update
Apr 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01431690
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 9, 2011
Start date
Aug 2011
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Apr 24, 2015

Study contacts

Michael H Davidson, MD, FACC
study director · Omthera Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Warfarin · Omacor

Start the discussion